ClinicalTrials.gg
CompletedNCT07269327Updated Mar 18, 2026

An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin

A Phase 1 interventional study of Desogestrel and ethinylestradiol fixed dose combination and Follitropin alfa/lutropin alfa in Fertility, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in United Kingdom. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.

Enrollment
29th of 30
24 · median 159
Started
2025
the only one that year
Phase 1
2 of 30
none open now
Registered
28th of 30
by date
Lead sponsor
3 of 30
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Among the 30 studies testing follitropin alfa in Infertility, this one is the 29th largest by enrollment, is the only one that started in 2025, is one of 2 in phase 1, and was the 28th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About follitropin alfa

follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing follitropin alfa in Infertility, or all of them as a file.
02

Study summary

The purpose of this study is to assess the Pharmacokinetic (PK) of Recombinant human follicle-stimulating hormone (follitropin alfa) (r-hFSH) and Recombinant human luteinizing hormone (lutropin alfa) (r-hLH) following a single subcutaneous injection of Pergoveris in pituitary-suppressed healthy female participants of Japanese or Caucasian origin. Study details include:

Study Duration: Approximately 9 weeks Treatment Duration: Approximately 4 weeks downregulation with Marvelon® and a single dose of Pergoveris.

Visit Frequency: Once in the Screening period, twice in the Downregulation period, and 8 continuous days in the study site during the Confinement period.

03

Conditions studied

  • Fertility

Browse trials for

Keywords

  • Clinical pharmacology
  • gonadotropins
  • infertility
  • prefilled pen
  • ethnicity
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant who are overtly healthy, as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring
  • Participant who have a negative urine pregnancy test before starting Marvelon and on the day before the Pergoveris dose (Day -1)
  • Participant who have a normal baseline FSH (\< 12 IU/L) and E2 levels less than or equal (\<=) 100 picogram per mililiter (pg/mL) and follicles \<= 11 millimeter (mm) in diameter at Screening
  • Participant who have a normal ThinPrep® cytologic test (TCT) during Screening
  • Other protocol defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Participant with any condition that, in the Investigator's opinion, constitutes an inappropriate risk or a for participation in the study or that could interfere with the study objectives, conduct, or evaluation
  • Participants with any abnormalities of the genital organs as determined by gynecological examination and transvaginal ultrasound scan (TVUS) and based on the Investigator's judgment (e.g. ovarian tumors, nonfunctional ovarian cysts, and endometrial hyperplasia)
  • Participant with imminent planned major surgery
  • Participant with a History of tumors of the pituitary gland or hypothalamus
  • Other protocol defined exclusion criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1: Japanese Female Participants

    Drug: Desogestrel and ethinylestradiol fixed dose combination · Combination Product: Follitropin alfa/lutropin alfa

  • Experimental
    Group 2: Caucasian Female Participants

    Drug: Desogestrel and ethinylestradiol fixed dose combination · Combination Product: Follitropin alfa/lutropin alfa

Interventions

  • DrugDesogestrel and ethinylestradiol fixed dose combination

    Drug pages: Desogestrel · Ethinyl Estradiol

    Participants will self-administer one tablet of desogestrel and ethinylestradiol fixed dose combination once daily to ensure downregulation.

    Also known as: Marvelon

  • Combination productFollitropin alfa/lutropin alfa

    Drug pages: Follitropin alfa · Lutropin alfa

    Participants will receive a combination product of follitropin alfa and lutropin alfa subcutaneously (SC) on Day 1 after confirmation of down regulation.

    Also known as: Pergoveris

06

What researchers measure

Primary outcomes

  1. Baseline-Adjusted Area Under the Serum Concentration- Time Curve from Time Zero to Last Quantifiable Sampling Time After Administration (AUC0-tlast,adj) for both r-hFSH and r-hLH

    Time frame: Predose (baseline), 2 hour(hr), 4, 6, 7, 8, 9, 10, 12,15 and 18hr post-dose on Day 1; 24hr, 36hr post-dose on Day 2; 48hr post-dose on Day 3; 72 hr post dose on Day 4; 96hr post-dose on Day 5; 120hr post-dose on Day 6 and 168hr post-dose on Day 8

  2. Baseline- Adjusted Maximum Observed Serum Concentration (Cmax,adj), for both r-hFSH and r-hLH

    Time frame: Predose (baseline), 2 hour(hr), 4, 6, 7, 8, 9, 10, 12,15 and 18hr post-dose on Day 1; 24hr, 36hr post-dose on Day 2; 48hr post-dose on Day 3; 72 hr post dose on Day 4; 96hr post-dose on Day 5; 120hr post-dose on Day 6 and 168hr post-dose on Day 8

Secondary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    Time frame: From Screening to End of Study (approximately 9 weeks)

  2. Number of Participants with Clinically Significant Change From Baseline in Laboratory Parameters

    The laboratory assessment includes biochemistry, coagulation, hematology, hormonal, urinalysis parameters.

    Time frame: Baseline (Day -1) upto end of study (approximately 9 weeks)

  3. Number of Participants With Abnormal Vital Signs

    Vital signs included body temperature, systolic and diastolic blood pressure, respiratory rate and pulse rate and electrocardiogram (ECG) measurements.

    Time frame: Up to end of study (Approximately 9 Weeks)

  4. Participants Serum Estradiol (E2) levels

    Time frame: Screening (Day -53 to Day -24) and Day-1

  5. Number of Participants With Abnormal Follicle Size and Number measured by Transvaginal Ultrasound (TVUS)

    Time frame: Day-2 to Day-1 (Downregulation), and Day 6 to Day 8

  6. Number of Participants Experiencing Local Reactions

    Pain, redness, swelling, bruising, and itching around the injection site will be assessed.

    Time frame: Baseline up to end of study (approximately 9 weeks)

  7. Serum Concentration of Baseline- Adjusted r-hFSH and r-hLH

    Time frame: Predose (baseline), 2 hour(hr), 4, 6, 7, 8, 9, 10, 12,15 and 18hr post-dose on Day 1; 24hr, 36hr post-dose on Day 2; 48hr post-dose on Day 3; 72 hr post dose on Day 4; 96hr post-dose on Day 5; 120hr post-dose on Day 6 and 168hr post-dose on Day 8

07

Study locations

1 site
  • Fortrea Clinical Research Unit Ltd
    Leeds, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website http://bit.ly/IPD21

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Mar 2026, 3 months.

Of 28 phase 1 interventional studies under Infertility, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 8, 2025
StartActual
Nov 24, 2025
Primary completionActual
Mar 9, 2026
CompletionActual
Mar 9, 2026
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07269327
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Nov 24, 2025
Primary completion
Mar 9, 2026
Completion
Mar 9, 2026
Last update
Mar 18, 2026

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Follitropin alfa · Lutropin alfa

Start the discussion